Skip to main content

SCYNEXIS, Inc.

corporate_fare Company Profile

SCYNEXIS, Inc.

SCYX·NASDAQ·Life Sciences·CIK 0001178253

SCYNEXIS, Inc. is a pharmaceutical company focused on developing treatments for severe rare diseases, with a primary focus on difficult-to-treat and drug-resistant fungal infections. The company develops its proprietary antifungal platform called "fungerps," which are triterpenoids, a novel class of antifungal agents. These agents are glucan synthase inhibitors and have demonstrated activity against a broad range of human fungal pathogens, including Candida, Aspergillus, Pneumocystis, Coccidioides, Histoplasma, Blastomyces genera, and most common mucorales species, including multidrug-resistant strains. Ibrexafungerp, the first fungerp, was approved by the U.S. Food and Drug Administration (FDA) as BREXAFEMME (ibrexafungerp tablets) in 2021 for vulvovaginal candidiasis (VVC) and in 2022 for the reduction in the incidence of recurrent vulvovaginal candidiasis (rVVC). Ibrexafungerp was licensed to GSK in May 2023. A second-generation fungerp, SCY-247, is currently in clinical trials, and other compounds from the fungerp platform are in earlier development stages. The FDA has granted SCY-247 Qualified Infectious Disease Product status and Fast Track designations for its oral formulation. The company recently completed the single and multiple ascending dose portions of a Phase 1 study for oral SCY-247 in 88 healthy subjects. This study evaluated the safety, tolerability, and pharmacokinetics of SCY-247 at single ascending doses from 50mg to 900mg and multiple ascending doses from 50mg to 300mg, once daily for 7 days. A total of 66 participants received SCY-247 and 22 received placebo across these cohorts, and SCY-247 was well tolerated.

SCYNEXIS, Inc. (NASDAQ:SCYX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for SCYX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 18 rated 8 or above. Recent SEC coverage for SCYX spans 10-Q, 8-K, 424B3, S-3.

Recent high-impact activity:

  • SCYNEXIS Q3 Loss Narrows to $8.5M; $63.2M Cash Funds Operations Into 2029
  • SCY-770 Phase 1 Shows Favorable Safety, Phase 2 in ADPKD Set for Q4
  • SCYNEXIS Secures Up to $214M BARDA Contract to Advance SCY-247 Antifungal
  • BARDA Awards SCYNEXIS Up to $214M Non-Dilutive Funding for SCY-247 Antifungal
  • SCYNEXIS Q2: Cash Runway Into 2029, Phase 1 Data for Kidney Disease Drug Due Q3

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$20.6M
Net Income
-$8.61M
Diluted EPS
-$0.17
Op. Cash Flow
-$5.28M
Operating Income
-$16.07M
Cash & Equivalents
$21.26M
Debt / Equity
0.00×
Net Margin
-41.8%
Shares Outstanding
43.54M sh
Source: 10-K · filed 2026-03-04 · accession 0001178253-26-000007

Short Interest & Short Volume

5.55 days to cover

FINRA reported short interest of 450,240 shares in SCYX as of the October 30, 2026 settlement, a 7.1% increase from the prior period — about 5.5 days to cover at its recent average daily volume. On November 20, 2026, 38.2% of SCYX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)450,240 shares as of October 30, 2026
Change vs prior period▲ 7.1%
Days to cover5.55 at avg daily volume of 81,053
Daily short volume (FINRA facilities)38.2% of 53,785 shares on November 20, 2026
5-day average short volume54.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for SCYX, detected from its recent SEC filings · based on capital-structure filings through 2026-11-05.

1 shelf registrationreverse split

Shelf Renewal, Not a Raise · No New Securities or Fees

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with S →
$2.38
52-week range · as of 2026-11-05 $2.38 – $9.12
Market cap
$23.69M
Volume
156K (2.1× avg)
3-mo avg 75.3K
Live data · 2026-11-21 16:44 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed SCYX - Latest Insights

SCYX
Nov 05, 2026, 8:01 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $3.84
Real-time Price: $2.38 info
Change: -$1.46 (-38%) info
Market Cap: $23.689M info
SCYX
Oct 06, 2026, 7:53 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $5.18
Real-time Price: $2.38 info
Change: -$2.80 (-54%) info
Market Cap: $23.689M info
SCYX
Sep 28, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.71
Real-time Price: $2.38 info
Change: -$2.33 (-50%) info
Market Cap: $23.689M info
SCYX
Sep 28, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $6.46
Real-time Price: $2.38 info
Change: -$4.08 (-63%) info
Market Cap: $23.689M info
SCYX
Aug 10, 2026, 4:30 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $5.27
Real-time Price: $2.38 info
Change: -$2.89 (-55%) info
Market Cap: $23.689M info
SCYX
Aug 10, 2026, 4:01 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $5.16
Real-time Price: $2.38 info
Change: -$2.78 (-54%) info
Market Cap: $23.689M info
SCYX
Jun 30, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.90
Real-time Price: $2.38 info
Change: -$1.52 (-39%) info
Market Cap: $23.689M info
SCYX
Jun 26, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $3.85
Real-time Price: $2.38 info
Change: -$1.47 (-38%) info
Market Cap: $23.689M info
SCYX
May 29, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.705
Real-time Price: $2.38 info
Change: Reverse Stock Split info
Market Cap: $23.689M info
SCYX
May 22, 2026, 4:20 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.680
Real-time Price: $2.38 info
Change: Reverse Stock Split info
Market Cap: $23.689M info
SCYX
May 22, 2026, 4:15 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.680
Real-time Price: $2.38 info
Change: Reverse Stock Split info
Market Cap: $23.689M info
SCYX
May 11, 2026, 4:01 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.8241
Real-time Price: $2.38 info
Change: Reverse Stock Split info
Market Cap: $23.689M info
SCYX
May 08, 2026, 5:17 PM EDT
Filing Type: 424B3
Importance Score:
8
Price at Filing: $0.9157
Real-time Price: $2.38 info
Change: Reverse Stock Split info
Market Cap: $23.689M info
SCYX
May 01, 2026, 4:03 PM EDT
Filing Type: S-3
Importance Score:
9
Price at Filing: $0.9903
Real-time Price: $2.38 info
Change: Reverse Stock Split info
Market Cap: $23.689M info
SCYX
Apr 27, 2026, 4:18 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $1.01
Real-time Price: $2.38 info
Change: Reverse Stock Split info
Market Cap: $23.689M info
SCYX
Apr 20, 2026, 5:24 PM EDT
Filing Type: PRE 14A
Importance Score:
9
Price at Filing: $1.05
Real-time Price: $2.38 info
Change: Reverse Stock Split info
Market Cap: $23.689M info
SCYX
Apr 17, 2026, 4:15 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $1.04
Real-time Price: $2.38 info
Change: Reverse Stock Split info
Market Cap: $23.689M info
SCYX
Apr 02, 2026, 8:01 AM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $0.850
Real-time Price: $2.38 info
Change: Reverse Stock Split info
Market Cap: $23.689M info
SCYX
Mar 31, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.8723
Real-time Price: $2.38 info
Change: Reverse Stock Split info
Market Cap: $23.689M info
SCYX
Mar 31, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.863
Real-time Price: $2.38 info
Change: Reverse Stock Split info
Market Cap: $23.689M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets